{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Familial tumour syndromes of the central and peripheral nervous system",
      "relation": "contraindication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "n_vemurafenib",
          "type": "Drug",
          "label": "Vemurafenib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_dabrafenib",
          "type": "Drug",
          "label": "Dabrafenib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_trametinib",
          "type": "Drug",
          "label": "Trametinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_sunitinib",
          "type": "Drug",
          "label": "Sunitinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_sorafenib",
          "type": "Drug",
          "label": "Sorafenib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_everolimus",
          "type": "Drug",
          "label": "Everolimus",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_cyclophosphamide",
          "type": "Drug",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_irinotecan",
          "type": "Drug",
          "label": "Irinotecan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_etoposide",
          "type": "Drug",
          "label": "Etoposide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_carboplatin",
          "type": "Drug",
          "label": "Carboplatin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_temozolomide",
          "type": "Drug",
          "label": "Temozolomide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_bevacizumab",
          "type": "Drug",
          "label": "Bevacizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_familial_tumour_syndromes",
          "type": "Disease",
          "label": "Familial tumour syndromes of the central and peripheral nervous system",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_vemurafenib",
          "type": "Target",
          "label": "OffTarget_Vemurafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_vemurafenib",
          "type": "Pathway",
          "label": "RiskPathway_Vemurafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_vemurafenib",
          "type": "Phenotype",
          "label": "AdversePhenotype_Vemurafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_dabrafenib",
          "type": "Target",
          "label": "OffTarget_Dabrafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_dabrafenib",
          "type": "Pathway",
          "label": "RiskPathway_Dabrafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_dabrafenib",
          "type": "Phenotype",
          "label": "AdversePhenotype_Dabrafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_trametinib",
          "type": "Target",
          "label": "OffTarget_Trametinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_trametinib",
          "type": "Pathway",
          "label": "RiskPathway_Trametinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_trametinib",
          "type": "Phenotype",
          "label": "AdversePhenotype_Trametinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_sunitinib",
          "type": "Target",
          "label": "OffTarget_Sunitinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_sunitinib",
          "type": "Pathway",
          "label": "RiskPathway_Sunitinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_sunitinib",
          "type": "Phenotype",
          "label": "AdversePhenotype_Sunitinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_sorafenib",
          "type": "Target",
          "label": "OffTarget_Sorafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_sorafenib",
          "type": "Pathway",
          "label": "RiskPathway_Sorafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_sorafenib",
          "type": "Phenotype",
          "label": "AdversePhenotype_Sorafenib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_everolimus",
          "type": "Target",
          "label": "OffTarget_Everolimus",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_everolimus",
          "type": "Pathway",
          "label": "RiskPathway_Everolimus",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_everolimus",
          "type": "Phenotype",
          "label": "AdversePhenotype_Everolimus",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_cyclophosphamide",
          "type": "Target",
          "label": "OffTarget_Cyclophosphamide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_cyclophosphamide",
          "type": "Pathway",
          "label": "RiskPathway_Cyclophosphamide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_cyclophosphamide",
          "type": "Phenotype",
          "label": "AdversePhenotype_Cyclophosphamide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_irinotecan",
          "type": "Target",
          "label": "OffTarget_Irinotecan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_irinotecan",
          "type": "Pathway",
          "label": "RiskPathway_Irinotecan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_irinotecan",
          "type": "Phenotype",
          "label": "AdversePhenotype_Irinotecan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_etoposide",
          "type": "Target",
          "label": "OffTarget_Etoposide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_etoposide",
          "type": "Pathway",
          "label": "RiskPathway_Etoposide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_etoposide",
          "type": "Phenotype",
          "label": "AdversePhenotype_Etoposide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_carboplatin",
          "type": "Target",
          "label": "OffTarget_Carboplatin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_carboplatin",
          "type": "Pathway",
          "label": "RiskPathway_Carboplatin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_carboplatin",
          "type": "Phenotype",
          "label": "AdversePhenotype_Carboplatin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_temozolomide",
          "type": "Target",
          "label": "OffTarget_Temozolomide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_temozolomide",
          "type": "Pathway",
          "label": "RiskPathway_Temozolomide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_temozolomide",
          "type": "Phenotype",
          "label": "AdversePhenotype_Temozolomide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_bevacizumab",
          "type": "Target",
          "label": "OffTarget_Bevacizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_bevacizumab",
          "type": "Pathway",
          "label": "RiskPathway_Bevacizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_bevacizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Bevacizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Vemurafenib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_vemurafenib",
          "type": "Drug",
          "label": "Vemurafenib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Dabrafenib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_dabrafenib",
          "type": "Drug",
          "label": "Dabrafenib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Trametinib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_trametinib",
          "type": "Drug",
          "label": "Trametinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Sunitinib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_sunitinib",
          "type": "Drug",
          "label": "Sunitinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Sorafenib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_sorafenib",
          "type": "Drug",
          "label": "Sorafenib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Everolimus",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_everolimus",
          "type": "Drug",
          "label": "Everolimus",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_cyclophosphamide",
          "type": "Drug",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Irinotecan",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_irinotecan",
          "type": "Drug",
          "label": "Irinotecan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Etoposide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_etoposide",
          "type": "Drug",
          "label": "Etoposide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Carboplatin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_carboplatin",
          "type": "Drug",
          "label": "Carboplatin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Temozolomide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_temozolomide",
          "type": "Drug",
          "label": "Temozolomide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Bevacizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_bevacizumab",
          "type": "Drug",
          "label": "Bevacizumab",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "n_vemurafenib",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "Kaplan-Meier 分析显示潜在的风险"
        },
        {
          "source": "n_dabrafenib",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "与 Vemurafenib 有相似临床特征"
        },
        {
          "source": "n_trametinib",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "临床资料表明相关风险"
        },
        {
          "source": "n_sunitinib",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "已知可能对神经系统有影响"
        },
        {
          "source": "n_sorafenib",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "其副作用可能相关"
        },
        {
          "source": "n_everolimus",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "可能影响病理进程"
        },
        {
          "source": "n_cyclophosphamide",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "有可能引发合并症"
        },
        {
          "source": "n_irinotecan",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.45,
          "agent": "Proponent",
          "rationale": "对细胞增殖的影响值得关注"
        },
        {
          "source": "n_etoposide",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.45,
          "agent": "Proponent",
          "rationale": "其风险已在文献中报道"
        },
        {
          "source": "n_carboplatin",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "可能与神经病理有关"
        },
        {
          "source": "n_temozolomide",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "潜在的负面影响"
        },
        {
          "source": "n_bevacizumab",
          "target": "n_familial_tumour_syndromes",
          "relation": "causes",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "相关的查询表明风险"
        },
        {
          "source": "drug_vemurafenib",
          "target": "n_ot_vemurafenib",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_vemurafenib",
          "target": "n_rp_vemurafenib",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_vemurafenib",
          "target": "n_adv_vemurafenib",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_vemurafenib",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_dabrafenib",
          "target": "n_ot_dabrafenib",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_dabrafenib",
          "target": "n_rp_dabrafenib",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_dabrafenib",
          "target": "n_adv_dabrafenib",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_dabrafenib",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_trametinib",
          "target": "n_ot_trametinib",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_trametinib",
          "target": "n_rp_trametinib",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_trametinib",
          "target": "n_adv_trametinib",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_trametinib",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_sunitinib",
          "target": "n_ot_sunitinib",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_sunitinib",
          "target": "n_rp_sunitinib",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_sunitinib",
          "target": "n_adv_sunitinib",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_sunitinib",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_sorafenib",
          "target": "n_ot_sorafenib",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_sorafenib",
          "target": "n_rp_sorafenib",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_sorafenib",
          "target": "n_adv_sorafenib",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_sorafenib",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_everolimus",
          "target": "n_ot_everolimus",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_everolimus",
          "target": "n_rp_everolimus",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_everolimus",
          "target": "n_adv_everolimus",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_everolimus",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_cyclophosphamide",
          "target": "n_ot_cyclophosphamide",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_cyclophosphamide",
          "target": "n_rp_cyclophosphamide",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_cyclophosphamide",
          "target": "n_adv_cyclophosphamide",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_cyclophosphamide",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_irinotecan",
          "target": "n_ot_irinotecan",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_irinotecan",
          "target": "n_rp_irinotecan",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_irinotecan",
          "target": "n_adv_irinotecan",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_irinotecan",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_etoposide",
          "target": "n_ot_etoposide",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_etoposide",
          "target": "n_rp_etoposide",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_etoposide",
          "target": "n_adv_etoposide",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_etoposide",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_carboplatin",
          "target": "n_ot_carboplatin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_carboplatin",
          "target": "n_rp_carboplatin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_carboplatin",
          "target": "n_adv_carboplatin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_carboplatin",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_temozolomide",
          "target": "n_ot_temozolomide",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_temozolomide",
          "target": "n_rp_temozolomide",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_temozolomide",
          "target": "n_adv_temozolomide",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_temozolomide",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        },
        {
          "source": "drug_bevacizumab",
          "target": "n_ot_bevacizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能靶点作用导致不良反应"
        },
        {
          "source": "n_ot_bevacizumab",
          "target": "n_rp_bevacizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp_bevacizumab",
          "target": "n_adv_bevacizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发肿瘤等不良表型"
        },
        {
          "source": "n_adv_bevacizumab",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在风险，可能抵消疗效"
        }
      ],
      "round_index": 1
    },
    "history": {
      "round": 1,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.65,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Vemurafenib",
                "pro": [
                  "n_vemurafenib"
                ],
                "con": [
                  "n_adv_vemurafenib"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H2",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.65,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Dabrafenib",
                "pro": [
                  "n_dabrafenib"
                ],
                "con": [
                  "n_adv_dabrafenib"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H3",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.65,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Trametinib",
                "pro": [
                  "n_trametinib"
                ],
                "con": [
                  "n_adv_trametinib"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H4",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Sunitinib",
                "pro": [
                  "n_sunitinib"
                ],
                "con": [
                  "n_adv_sunitinib"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H5",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Sorafenib",
                "pro": [
                  "n_sorafenib"
                ],
                "con": [
                  "n_adv_sorafenib"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H6",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Everolimus",
                "pro": [
                  "n_everolimus"
                ],
                "con": [
                  "n_adv_everolimus"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H7",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Cyclophosphamide",
                "pro": [
                  "n_cyclophosphamide"
                ],
                "con": [
                  "n_adv_cyclophosphamide"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H8",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.45,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Irinotecan",
                "pro": [
                  "n_irinotecan"
                ],
                "con": [
                  "n_adv_irinotecan"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H9",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.45,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Etoposide",
                "pro": [
                  "n_etoposide"
                ],
                "con": [
                  "n_adv_etoposide"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.4,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Carboplatin",
                "pro": [
                  "n_carboplatin"
                ],
                "con": [
                  "n_adv_carboplatin"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.4,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Temozolomide",
                "pro": [
                  "n_temozolomide"
                ],
                "con": [
                  "n_adv_temozolomide"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.3,
            "safety_risk": 0.8,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.4,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "AdversePhenotype_Bevacizumab",
                "pro": [
                  "n_bevacizumab"
                ],
                "con": [
                  "n_adv_bevacizumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "交联的 Drug→Disease 路径表明机制相关性"
            ],
            "safety_risk": [
              "Skeptic 指出潜在的不良表型风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏足够的图结构进行全面评估"
          ]
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65
    },
    "heuristic_priors": []
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Vemurafenib",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Vemurafenib 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Dabrafenib",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Dabrafenib 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H3",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Trametinib",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Trametinib 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H4",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Sunitinib",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Sunitinib 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H5",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Sorafenib",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Sorafenib 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H6",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Everolimus",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Everolimus 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H7",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Cyclophosphamide",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Cyclophosphamide 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H8",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Irinotecan",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Irinotecan 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H9",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Etoposide",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Etoposide 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H10",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Carboplatin",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Carboplatin 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H11",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Temozolomide",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Temozolomide 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      },
      {
        "hypothesis_id": "H12",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "AdversePhenotype_Bevacizumab",
            "expectation": "若风险存在，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Bevacizumab 对神经系统的潜在影响",
          "评估其对 Familial tumour syndromes 的具体影响"
        ]
      }
    ],
    "seed_request": {
      "should_regenerate": true,
      "reason": "支持弱且冲突强，需引入新的候选以增强机制连通性和覆盖性。",
      "n": 4
    }
  }
}